Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis

Affiliations

• ¹ Juvenile Myositis Pathogenesis and Therapeutics Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA hanna.kim@nih.gov.
• ² Pediatric Clinical Trials Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
• ³ Office of the Clinical Director, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
• ⁴ Translational Immunology Section, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
• ⁵ Biostatistics and Clinical Epidemiology Service, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
• ⁶ Rehabilitation Medicine Department, Physical Therapy Section, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
• ⁷ Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
• ⁸ Pediatric Rheumatology, Cook Children's Medical Center, Fort Worth, Texas, USA.
• ⁹ Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
• ¹⁰ Department of Rheumatology, Children's Hospital Colorado, Aurora, Colorado, USA.
• ¹¹ Pediatrics Rheumatology, University of Colorado Denver, Denver, Colorado, USA.
• ¹² Division of Rheumatology, Hospital for Sick Children, Toronto, Ontario, Canada.
• ¹³ Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
• ¹⁴ Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
• ¹⁵ Dermatology Branch, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
• ¹⁶ Environmental Autoimmunity Group, NIEHS/NIH/DHHS, Bethesda, Maryland, USA.